Niagen Bioscience, Inc.
NAGE
$4.78
-$0.04-0.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.19% | 32.86% | 36.84% | 37.59% | 37.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.19% | 32.86% | 36.84% | 37.59% | 37.41% |
| Cost of Revenue | 11.05% | 29.10% | 20.40% | 28.21% | 32.32% |
| Gross Profit | 19.27% | 35.02% | 47.71% | 43.66% | 40.66% |
| SG&A Expenses | 83.10% | 19.10% | 22.49% | 10.00% | -18.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.16% | 24.07% | 21.47% | 12.34% | 3.04% |
| Operating Income | -70.43% | 164.42% | 1,344.14% | 752.80% | 4,332.74% |
| Income Before Tax | -40.89% | 155.59% | 25,013.33% | 1,163.21% | 6,464.91% |
| Income Tax Expenses | -4.26% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.44% | 143.77% | 24,160.00% | 1,129.07% | 6,197.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.44% | 143.77% | 24,160.00% | 1,129.07% | 6,197.37% |
| EBIT | -70.43% | 164.42% | 1,344.14% | 752.80% | 4,332.74% |
| EBITDA | -68.47% | 145.62% | 7,000.00% | 1,064.47% | 15,108.33% |
| EPS Basic | -44.59% | 132.39% | 22,850.00% | 1,101.54% | 6,120.00% |
| Normalized Basic EPS | -68.59% | 144.16% | 29,600.00% | 1,124.39% | 6,655.56% |
| EPS Diluted | -42.13% | 150.00% | 20,100.00% | 700.00% | -- |
| Normalized Diluted EPS | -68.76% | 129.14% | 27,200.00% | 1,058.54% | 6,266.67% |
| Average Basic Shares Outstanding | 3.78% | 5.01% | 4.88% | 3.43% | 2.43% |
| Average Diluted Shares Outstanding | 4.41% | 11.38% | 14.14% | 10.64% | 8.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |